BrightSpring Health Services raised its full-year revenue guidance to $15.26 billion at the midpoint, up from $14.98 billion, after reporting second-quarter revenue of $3.87 billion that beat analyst estimates by 5.9%. Adjusted EPS of $0.45 exceeded expectations by 13%, and adjusted EBITDA of $205.5 million came in 5% above consensus. CEO Jon Rousseau highlighted 30% revenue growth and 31% script growth in the Specialty and Infusion pharmacy business, driven by new limited distribution drug launches, while acknowledging ongoing headwinds in the Home and Community Pharmacy segment from customer exits and regulatory pressures. The company also raised its full-year EBITDA guidance to $832.5 million at the midpoint, above analyst estimates of $816.3 million.
BrightSpring Health Services, Inc. Common StockRaised full-year revenue and EBITDA guidance, with Q2 results beating estimates.
